NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immutep Limited (IMMP) Stock Analysis

Immutep Limited (IMMP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMMP

$0.36

−$0.01 (−2.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMMP with… →

IMMP Key Statistics

As of Sep 4, 2026
Trading
Open
$0.38
Previous Close
$0.37
Day's Range
0.36–0.38
52-Week Range
0.29–3.53
Volume
62.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.20
Valuation
Market Cap
$53.78M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.70
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.39
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.72M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
147.37M
1-Year Return
−77.78%
Dividend and dates
Avg Volume
269.68K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMMP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−87.41%
2025+31.80%
2024−9.58%
2023+37.14%
2022−46.65%
2021+4.46%
2020+75.42%
2019−2.72%
2018+17.20%
2017−32.91%
2016 (partial year)−22.00%

As of September 4, 2026.

IMMP Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$42.72M—
2023$0.00−$39.90M—
2022$170.37K−$32.21M−18906.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$46.56M−$42.72M—
2023$0.00—−$41.43M−$39.90M—
2022$170.37K—−$33.84M−$32.21M−18906.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

IMMP Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMMPBiotechnology medianvs median
P/S ratio2.7015.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Immutep Limited (IMMP) is capitalised at $53.78M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector.

Over the past 52 weeks the price has ranged from $0.29 to $3.53. The most recent close on file for IMMP is $0.36, dated September 4, 2026. That is −$0.01 (−2.70%) against the previous close. The latest close sits 24.14% above that 52-week low.

Financial Health

In fiscal 2024, Immutep Limited reported revenue of $0.00. The same year closed with a net loss of $42.72M. The reported profit margin is 0%. Trailing earnings per share are −0.39.

Across the 3 fiscal years on file, revenue moves from $170.37K in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.7. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −77.78%. Measured over 10 years, that is −18.64% a year compounded. Beta against the wider market is reported at 2.2. Daily returns over the trailing 10 years annualize to a volatility of 97.46%.

Growth & Income

The record shows no dividend for IMMP.

So far in 2026 the price is −87.41%. Across the complete calendar years on file, 2020 returned +75.42% and 2022 returned −46.65%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Immutep Limited (IMMP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immutep Limited IMMP $53.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immutep Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immutep Limited

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Visit website →